What does SLU-PP-332 do? Benefits and evidence
An exercise-mimicking research chemical with mouse benefits and no human dosing trials.
Also called: SLU PP 332, SLUPP332, SLUPP-332.
Exercise mimetics · Pan-estrogen-related receptor (ERRα/β/γ) agonist · Evidence: Animal studies only.
SLU-PP-332 is a small molecule, not a peptide. It activates cell switches involved in energy use and improved endurance and fat metabolism in mice. No published study has dosed people, and no human trial was registered in this search. Oral absorption is poor in preclinical work. Human benefits, safe doses and long-term harms are unknown.
- In mice, it increased how long they could run on a treadmill. (animal)
- In mice with obesity, it reduced fat gain. (animal)
- Some users report easier cardio or more training capacity, others no effect; no study has tested it in people. (Reported by users)
Uses in the sources
- Users report easier cardio or more training capacity; controlled human benefits are unproven. (Reported by users) (source)
- Users report adding it during weight loss. The controlled fat-loss evidence comes from mice. (Reported by users) (source)
- Used online for more energy; some reports instead describe fatigue or no benefit. (Reported by users) (source)
Related to SLU-PP-332
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
- 5-amino-1MQ: An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
Sources
- 2027 Prohibited List: Summary of Changes, UK Anti-Doping · 2026
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.